Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...

We can do better. We can build a system that provides coordinated high-quality care to every patient who needs it.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.

Orna Therapeutics and Vertex will use lipid nanoparticle system to develop gene-editing therapies for people with SCD and TDT ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

Morgan Stanley lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $456 and keeps an Equal Weight rating on the ...

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will encore data from the BEACON Phase 1/2 ...